ML267 free base
Based on 1 Customer Validation
ML267 free base is a blood-brain barrier permeable Antibacterial agent and bacterial phosphopantetheinyl transferase (PPTase) inhibitor, with an IC50 of 0.29 μM against Bacillus subtilis Sfp-PPTase and an IC50 of 8.1 μM against bacterial AcpS-PPTase. ML267 free base attenuates bacterial secondary metabolism, activity, and the production of Sfp-PPTase-dependent metabolites. ML267 free base inhibits the growth of Gram-positive bacteria, including Methicillin (HY-121544)-resistant Staphylococcus aureus. ML267 free base is applicable to research related to bacterial infections, including methicillin-resistant Staphylococcus aureus infections.
For research use only. We do not sell to patients.
- Purity: 98.45%
- CAS No.: 1542213-03-5
- Formula: C17H17ClF3N5OS
- Molecular Weight:431.86
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
ML267 (free base) (3.6 nM-114 μM; 15 min pre-incubation, 30 min reaction) potently inhibits bacterial Sfp-PPTase with an IC50 of 0.290 μM and shows no activity against human PPTase at concentrations up to 114 μM[1].
ML267 (free base) (up to 8.1 μM; 15 min pre-incubation, 60 min reaction) inhibits bacterial AcpS-PPTase with an IC50 of 8.1 μM[1].
ML267 (free base) (0.4-100 μg/mL; 16-20 h, 4 h resazurin) exhibits bactericidal activity against Gram-positive bacterial strains including methicillin-resistant Staphylococcus aureus, with MICs ranging from 1.7 to 6.3 μg/mL, and no activity against Gram-negative bacteria or fungi[1].
ML267 (free base) (0.53-1.1 μg/mL; 28 h) dose-dependently attenuates Sfp-PPTase-dependent surfactin production in Bacillus subtilis OKB105 by 33-41% at sublethal concentrations, with minimal impact on bacterial growth[1].
ML267 (free base) potently inhibits bacterial Sfp-type PPTase (IC50 = 0.29 μM) and AcpS-type PPTase (IC50 = 8.1 μM), with no activity against the human PPTase ortholog[2].
ML267 (free base) (0.156-40 μM; 6 h) inhibits the growth of Bacillus subtilis ATCC 21332 with a MIC of 5.0 μM[2].
ML267 (free base) (serial dilutions; 15 min with enzyme, 30 min with substrate) potently inhibits Sfp phosphopantetheinyl transferase with an IC50 of 290 nM in a qHTS assay[3].
ML267 (free base) (serial dilutions; 48 h) exhibits no significant cytotoxicity against HepG2 human hepatocarcinoma cells, with an IC50 greater than 57 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 human hepatocarcinoma cells
-
Concentration:serial dilutions
-
Incubation Time:48 h
-
Result:Showed no significant cytotoxicity against HepG2 cells, with an IC50 greater than 57 μM.
| Species | Dose | Route | T1/2 | Cmax | AUCinf | Vd | MRT | CL | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 3 mg/kg | i.v. | 2.4 h | 4114 ng/mL | 6983 ng·h/mL | 1.5 L/kg | 3.4 h | 7.2 mL/min/kg | / |
| Mice[1] | 30 mg/kg | i.p. | 2.0 h | 17633 ng/mL | 68860 ng·h/mL | / | / | / | / |
| Mice[3] | 3 mg/kg | i.v. | 2.4 h | / | 6983 ng·h/mL | 1.5 L/kg | 3.4 h | 7.2 mL/min/kg | / |
| Mice[3] | 30 mg/kg | i.p. | 2.0 h | 17633 ng/mL | 68860 ng·h/mL | / | / | / | 98.5 % |
ML267 free base (3-30 mg/kg; i.v., i.p.; single dose) achieves favorable systemic exposure and crosses the blood-brain barrier in healthy CD1 mice with no acute toxicity at tested doses[1].
ML267 free base (3-30 mg/kg; i.v., i.p.; single dose) exhibits favorable in vivo pharmacokinetic properties in male CD-1 mice, with 98.5% bioavailability after intraperitoneal administration at 30 mg/kg and a plasma-to-brain ratio of 2.1, and a half-life of 2.4 hours after intravenous administration at 3 mg/kg[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD1 (male, 6−8 weeks of age)[1]
-
Dosage:3 mg/kg (i.v.); 30 mg/kg (i.p.)
-
Administration:i.v.; single dose; i.p.; single dose
-
Result:Had a half-life (T1/2) of 2.4 h, maximum concentration (Cmax) of 4114 ng/mL, area under the curve (AUCinf) of 6983 h·ng/mL, volume of distribution (Vd) of 1.5 L/kg, mean residence time (MRT) of 3.4 h, clearance of 7.2 mL/min/kg, and plasma-to-brain ratio (P/B) of 2.5 following i.v. administration.
Had a half-life (T1/2) of 2.0 h, maximum concentration (Cmax) of 17633 ng/mL, area under the curve (AUCinf) of 68860 h·ng/mL, and plasma-to-brain ratio (P/B) of 2.1 following i.p. administration.
Noted no adverse clinical observations over 24 hours.
Chemical Information
-
CAS No. 1542213-03-5
-
Appearance Solid
-
Molecular Weight 431.86
-
Formula C17H17ClF3N5OS
-
Color White to off-white
-
SMILES
FC(F)(C1=CN=C(N2CCN(CC2)C(NC3=NC=CC(OC)=C3)=S)C(Cl)=C1)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Foley TL, et al. 4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth. J Med Chem. 2014 Feb 13;57(3):1063-78. [Content Brief]
[2]. Konno S, et al. A Chemoproteomics Approach to Investigate Phosphopantetheine Transferase Activity at the Cellular Level. Chembiochem. 2017;18(18):1855-1862. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ML267 free base Related Classifications
Cat. No.: HY-137502A
Powered by Bioz
- ML267
- 1542213-03-5
- ML 267
- ML-267
- Bacterial
- Escherichia coli BW25113
- nonribosomal peptide synthetases
- AcpS-PPTase
- phosphopantetheinyl transferase
- Bacillus subtilis Sfp-PPTase
- Candida albicans
- Gram-positive bacteria
- CD1 mice
- HepG2 human hepatocarcinoma cells
- methicillin-resistant Staphylococcus aureus
- Inhibitor
- inhibitor
- inhibit